IL33 and neoplasm: Unsurprisingly, effective tumor control required high numbers of TCF1neg effector CD8+ TILs, a condition met solely following PD1d/IL-2v/IL-33 ACT (Fig. 1e,f), where 75–90% of OT1 TILs were TCF1neg.